Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03821220
Other study ID # 0201-17-COM2
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 15, 2019
Est. completion date August 31, 2021

Study information

Verified date February 2019
Source Clalit Health Services
Contact Amnon Lahad, MD
Phone 972-52-3293484
Email amnonl@ekmd.huji.ac.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This three-arm clinical trial aims to improve levels of physical activity among Arabic- speaking residents of East Jerusalem with prediabetes. Levels of daily physical activity (assessed through activity trackers), dietary habits and self-assessed health will be compared between patients that receive only the activity tracker and written information (group A), receive the activity tracker, written information and a personalized physical activity prescription (group B), and those that receive in addition also intensive follow-up with motivational interview by physician assistants and a dietitian (group C)


Description:

This is a three-arm clinical trial studying the effect of providing activity trackers with intensive motivational interview by trained physician assistants, and dietitian counselling, on the levels of daily physical activity among Arabic- speaking residents of East Jerusalem with prediabetes from Clalit Health Services. In addition, this study will also assess healthy dietary changes, and self assessed health and quality of life.

The study will compare three groups (total 375, each group 125):

Group A - will receive activity trackers and written educational handouts in addition to their usual care.

Group B - will receive all of group A intervention components and also a personalized physical activity prescription.

Group C - will receive all of group B components and also intensive motivational interview support by trained physician assistants (3 sessions), and dietitian support (two sessions).

Each participant will be followed-up for six months, with data collection occurring at baseline, three months and six months. Data collection will include average weekly steps, blood pressure, anthropometric measurements, routine blood tests (including fasting glucose, HbA1C, and lipid profile), physical activity survey, Mediterranean dietary habits survey, Food Frequency Questionnaire, and quality of life survey.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 375
Est. completion date August 31, 2021
Est. primary completion date February 15, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria:

Pre-diabetes patients - Impaired fasting glucose at least twice between 100-125 mg/dL in the two years prior to the study; or HbA1C 5.7%-6.4% twice in the two years prior to the study; or one test of fasting glucose of 100-125 mg/dL, and one test of HbA1C between 5.7%-6.4% in the two years prior to the study.

Exclusion Criteria:

1. Diabetes including a doctor's diagnosis based on a medical file or a recurrence of fasting blood glucose values above 126 mg/dL in the year preceding the study or a glucose value greater than 200 mg/dL in the year prior to the study or HbA1C above 6.5%

2. Treatment with diabetes drugs other than metformin, as prescribed in the medical file with regular or chronic medications

3. Artificial lower limbs or inability to walk normally (eg: stroke with plegia)

4. Chronic obstructive pulmonary disease

5. Known heart disease (with impaired exercise tolerance)

6. Pregnancy

7. Medical conditions:

- a cardiac event/ Transient ischemic attack in the last year

- Cerebrovascular attack with residual impairment

- Surgery that required hospitalization in the last year

- Injury to lower limbs that prevents regular walking

- Malignancy excluding skin cancer small cell carcinoma or basal cell carcinoma

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Motivational Interview support and Dietitian support
Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
Activity tracker plus usual care
Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
Personalized physical activity prescription
Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Clalit Health Services Hebrew University of Jerusalem

Outcome

Type Measure Description Time frame Safety issue
Primary Physical activity level assessed through average weekly steps six months
Secondary Fasting glucose levels six months
Secondary HbA1C levels six months
Secondary Body Mass Index six months
Secondary Lipid profile six months
Secondary Blood pressure six months
Secondary Energy intake 500< kcal/d <6000 kcal/d Six months
Secondary Waist circumference six months
Secondary Fat intake 15 <gram/day<200 six months
Secondary Protein intake 10<gram/day<300 six months
Secondary Iron intake 0<mg/day<50 six months
Secondary Folic acid intake 15< µg/day<3000 six months
Secondary Vitamin A intake 20< µg RAE/day<2500 six months
Secondary Vitamin C intake 0<mg/day<2500 six months
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A